Advanced Filters
noise

A, Almada N Clinical Trials

A listing of A, Almada N clinical trials actively recruiting patients volunteers.

Found 11,120 clinical trials
E Elena Seminari, MD

Calcific Aortic Valve Disease:the Role of Bacteria as Trigger of a Chronic Inflammation

Calcific aoric valve disease (CAVD) is extremely common worldwide, affecting almost 50% of the population over 85 years of age, with a lethality higher than 50% at 2 years for symptomatic patients, unless aortic-valve replacement is performed. CAVD is characterized by slowly progressive fibro-calcific remodelling of the valve leaflets causing …

18 years of age All Phase N/A
G Gauruv Bose, MD

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS …

18 - 60 years of age All Phase N/A
g giuliano scarcelli, PhD

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

We have developed novel Brillouin microscopy and we are testing its potential for keratoconus and ectasia diagnostics. We plan to perform axial scans of the cornea in human volunteers in order to compare biomechanical properties of Keratoconus vs. Normal corneas and compare biomechanical properties of post-LASIK ectasia vs. normal corneas.

20 - 75 years of age All Phase N/A
S Sarah Ginn

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, …

18 years of age All Phase N/A

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with …

18 years of age All Phase N/A
M Muserref KELES, PhD

Validity and Reliability of a Turkish Version of MD Anderson Inventory Dysphagia Inventory

The purpose of this study is to M.D. Validity of the Turkish version of the Anderson Dysphagia Inventory for the Turkish population, reliability, and cultural adaptation.

18 - 85 years of age All Phase N/A

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.

18 - 99 years of age All Phase N/A
H Haijie Liu, MD,Ph.D

A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy

The goal of this observational study is to learn about in the development process of adverse reactions of anti-PD1 immunotherapy. The main question it aims to observe: The autoantibody profile of patients The adverse reactions of patients The changes of immune cells and cytokine in patients

18 years of age All Phase N/A
O Orlane Figaroa, MD

Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUC

The goal of this observational study is to evaluate the intravesical recurrence (IVR) rate after ureteroscopy (diagnostic or treatment) for upper tract urothelial carcinoma (UTUC) followed by an adjuvant single instillation of Mitomycin C (SI-MMC). The main question it aims to answer are: What is the total and time to …

18 years of age All Phase N/A
V Vincenzo Canzonieri, MD, PhD

Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).

The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue …

18 years of age Female Phase N/A

Simplify language using AI